by AACR
Patients with high tumor burden are predisposed to less favorable outcomes after chimeric antigen receptor T-cell (CAR T) therapy, but researchers say radiomic cytoreduction achieved during...
by Nature
As the stem cell transplantation (SCT) landscape has evolved, scientists say the balance between graft-versus-leukemia (GVL) and graft-versus-host disease (GVHD) effects has also shifted.
by Dr. Corey Cutler, MD, MPH
In the December President's Message, Dr. Corey Cutler, MD, MPH, reflects on an impactful year for ASTCT.
by Alex Kadhim
Researchers at Stanford University have conducted a phase 1 clinical trial (#NCT03233854) evaluating the combination of a bispecific chimeric antigen receptor (CAR) T-cell therapy targeting CD19...
by ASTCT Talks
Welcome to the second installment of an exclusive 8-part ASTCT Talks series, supported by an educational grant from Sanofi US.
by BJHaem
The potential for secondary myelodyspastic syndromes (MDS) following chimeric antigen receptor (CAR) T-cell therapy in children with acute lymphoblastic leukemia (ALL) is a real concern,...